Publication:
Large animal models in regenerative medicine and tissue engineering: to do or not to do

Simple item page
dc.affiliation.dptoUC3M. Departamento de Bioingenieríaes
dc.affiliation.grupoinvUC3M. Grupo de Investigación: Tissue Engineering and Regenerative Medicine (TERMeG)es
dc.contributor.authorRibitsch, Iris
dc.contributor.authorBaptista, Pedro Miguel
dc.contributor.authorLange-Consiglio, Anna
dc.contributor.authorMelotti, Luca
dc.contributor.authorPatruno, Marco
dc.contributor.authorJenner, Florien
dc.contributor.authorSchnabl-Feichter, Eva
dc.contributor.authorDutton, Luke C.
dc.contributor.authorConnolly, David J.
dc.contributor.authorSteenbeek, Frank G. Van
dc.contributor.authorDudhia, Jayesh
dc.contributor.authorPenning, Louis C.
dc.date.accessioned2023-02-17T09:16:02Z
dc.date.available2023-02-17T09:16:02Z
dc.date.issued2019-08
dc.descriptionProceedings of: TERMIS EU 2019, 27th-31st May 2019, Rhodes, Greece.en
dc.description.abstractRapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress in animal models is mutually beneficial for animals, researchers, human and veterinary patients. In this overview we describe advantages and disadvantages of various animal models including domesticated and companion animals used in regenerative medicine and tissue engineering to provide an informed choice of disease-relevant animal models.en
dc.description.sponsorshipWe would like to thank Niklas Dresen, Institute of Veterinary Anatomy, University Leipzig as well as John Breteler, Elfriede Cremer, Bernhard Cremer, and Elisabeth Schieder for the provided graphical support and Michaela Hauser for formatting the references. PB acknowledges the funded projects PI15/00563 and PI18/00529 from ISCIII, Spain.en
dc.format.extent28
dc.identifier.bibliographicCitationRibitsch, I. et al. (27th-31st May 2019). Large animal models in regenerative medicine and tissue engineering: to do or not to do [proceedings]. TERMIS EU 2019, Rhodes, Greece.en
dc.identifier.doihttps://doi.org/10.3389/fbioe.2020.00972
dc.identifier.isbn2296-4185
dc.identifier.publicationfirstpage1
dc.identifier.publicationissue972
dc.identifier.publicationlastpage28
dc.identifier.publicationtitleFrontiers in bioengineering and biotechnology (special issue TERMIS EU 2019)en
dc.identifier.publicationvolume8
dc.identifier.urihttps://hdl.handle.net/10016/36594
dc.identifier.uxxiCC/0000033317
dc.language.isoeng
dc.publisherFrontiersen
dc.relation.eventdate2019-05-27es
dc.relation.eventplaceGreciaes
dc.relation.eventtitleTERMIS EU 2019. Tissue Engineering Therapies: From concept to clinical translation and commercialisationen
dc.rights© 2020 Ribitsch, Baptista, Lange-Consiglio, Melotti, Patruno, Jenner, Schnabl-Feichter, Dutton, Connolly, van Steenbeek, Dudhia and Penning.en
dc.rightsAtribución 3.0 España*
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.ecienciaBiología y Biomedicinaen
dc.subject.otherLarge animal modelsen
dc.subject.otherSheepen
dc.subject.otherPigen
dc.subject.otherHorseen
dc.subject.otherDogen
dc.subject.otherRegenerative medicineen
dc.subject.otherTissue engineeringen
dc.subject.otherNaturally occurring diseaseen
dc.titleLarge animal models in regenerative medicine and tissue engineering: to do or not to doen
dc.typeconference proceedings*
dc.type.hasVersionVoR*
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Large_TERMIS_2019.pdf
Size:
966.14 KB
Format:
Adobe Portable Document Format
Download
Collections
DBIAB - TERMEG - Proceedings